Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 6Carcinoma, Renal Cell 4Neoplasms 3Neoplasm Metastasis 3Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Hematologic Neoplasms 1Colorectal Neoplasms 1

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × Introns × Clear all
NCT00015912 2013-01-25

Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
35 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡